The concomitant use of VYVANSE and CYP2D6 inhibitors may increase the exposure of dextroamphetamine, the active metabolite of VYVANSE compared to the use of the drug alone and increase the risk of serotonin syndrome. A selective serotonin reuptake inhibitor (SSRI), which is a medicine commonly used for anxiety and depression https://dietrichf836ibw1.azzablog.com/profile